PHAT

Phathom Pharmaceuticals, Inc.

• NASDAQ·10/12 13:27

  Phathom Pharmaceuticals Highlights VOQUEZNA Data At ACG 2026

• Benzinga·10/12 12:03

  Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;

• TipRanks·10/07 16:30

  Phathom’s Vonoprazan Trial Targets Episodic Heartburn Upside for PHAT Investors

• TipRanks·09/29 21:19

  Phathom Starts Phase 3 VOQUEZNA Trial in NERD

• TipRanks·09/29 12:15

  Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA

• Benzinga·09/29 12:05

  Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD

• TipRanks·09/21 17:56

  H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)

• Seeking Alpha·09/09 16:13

  Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

• Dow Jones·09/09 15:48

  Phathom Pharmaceuticals Price Target Announced at $10.00/Share by Leerink Partners

• Benzinga·09/09 15:38

  Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

• TipRanks·09/09 12:16

  Leerink starts Phathom Pharmaceuticals at Market Perform on limited upside

• TipRanks·09/09 10:10

  Phathom Pharmaceuticals initiated with a Market Perform at Leerink

• Dow Jones·08/17 14:04

  Phathom Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Barclays

• Dow Jones·08/17 14:04

  Phathom Pharmaceuticals Is Maintained at Overweight by Barclays

• Benzinga·08/17 13:57

  Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14